FINAL PROGRAMME

Recommendations

Info

XXX ExHIbITION FLOOR PLAN 01 @ 17 11 10 12 09 13 08 07 02A 16 03 ENTRANCE 06 14 05 04 ENTRANCE TO POSTER AREA ExHIbITION LIST Company booth # Aegerion 5 Amgen 14 B. Braun Avitum AG 2A Denka Seiken 8 DIADEXUS Inc 12 European Atherosclerosis Society 7 Fresenius Medical Care 9 Itamar Medical Ltd 17 Merck 3 Mercodia 16 NSFA 11 Randox Cardiology 1 Sanofi/Regeneron/Genzyme 4 Synageva Biopharma 10 Wisepress Medical Bookshop 6
SPONSOR AND ExHIbITOR PROFILES Aegerion Pharmaceuticals, Inc. 101 Main Street - Suite 1850 Cambridge, MA 02142 USA www.aegerion.com Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of novel life-altering therapies for patients with debilitating, often fatal, rare diseases. Founded in 2005, our emerging global organization is based in Cambridge, Massachusetts with an established presence in Europe, and is growing internationally. In 2013, we successfully launched in the US our first product, Juxtapid (lomitapide) as an adjunct to a low fat diet and other lipid lowering treatments, including apheresis, for patients with homozygous familial hypercholesterolemia (HoFH). Lomitapide is currently in review by the European Medicines Agency (EMA). The company’s mission statement is: To develop therapeutic compounds on behalf of people with serious diseases using the highest ethical standards with demonstrated patient benefits. Aegerion is motivated by its commitment to patients first. We are also attentive to our core values of integrity, innovation, responsibility to healthcare providers, development of employees and always – scientific excellence. Amgen (Europe) GmbH Dammstrasse 23 6301 Zug Switzerland www.amgen.com Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realise the new science’s promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com. Follow us on twitter at www.twitter.com/amgen. AstraZeneca SE-431 83 Mölndal Sweden www.astrazeneca.com AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. XXXI
Page 1 and 2: FINAL PROGRAMME Congress Organizers
Page 3 and 4: WELCOMING WORDS Dear Colleagues, It
Page 5 and 6: FACULTY LIST Marcello Arca, Italy J
Page 7 and 8: ACKNOWLEDGEMENTS CORPORATE PARTNERS
Page 9 and 10: SPONSORS EXHIBITORS INSTITUTIONAL S
Page 11 and 12: THE ANITSCHKOW PRIZE THE ANITSCHKOW
Page 13 and 14: GENERAL INFORMATION VENUE LYON Cong
Page 15 and 16: MANDATORY CONFLICT OF INTEREST DISC
Page 17 and 18: OVERVIEW OF MODERATED POSTER SESSIO
Page 19 and 20: Track 3: RISK FACTORS, EPIDEMIOLOGY
Page 21 and 22: MONDAY, JUNE 3, 2013 13.00-14.30 -
Page 23 and 24: Opening Ceremony SUNDAY JUNE 2, 201
Page 25 and 26: HALL NAME EULOGY OF DISTINGUISHED S
Page 27 and 28: MARCEL MéRIEUx (1870-1937) BIOCHEM
Page 29: VENUE FLOOR PLANS XXIX
Page 33 and 34: DENKA SEIKEN CO.,LTD. Nihonbashi Mi
Page 35 and 36: Kowa 105 Wharfedale Road Winnersh T
Page 37 and 38: Roche Grenzacherstrasse 124 4070 Sw
Page 39 and 40: SCIENTIFIC PROGRAMME SUNDAY, JUNE 2
Page 41 and 42: Sunday, June 2, 2013 11:00-20:30 Re
Page 43 and 44: Sunday, June 2, 2013 16:20-17:50 Fo
Page 45 and 46: SCIENTIFIC PROGRAMME MONDAY, JUNE 3
Page 47 and 48: Monday, June 3, 2013 08:30-10:30 Au
Page 49 and 50: Monday, June 3, 2013 10:50-12:40 Fo
Page 55 and 56: Monday, June 3, 2013 17:00-18:30 Au
Page 57: SCIENTIFIC PROGRAMME TUESDAY, JUNE
Page 60 and 61: Tuesday, June 4, 2013 10:50-12:40 F
Page 69: SCIENTIFIC PROGRAMME WEDNESDAY, JUN
Page 72 and 73: Wednesday, June 5, 2013 10:50-12:40
Page 74 and 75: Wednesday, June 5, 2013 10:50-12:40
Page 76 and 77: Written by top experts in the field
Page 78 and 79: Monday, June 3, 2013 13:40-14:40 Mo
Page 80 and 81:
Monday, June 3, 2013 13:40-14:40 Mo
Page 82 and 83:
Monday, June 3, 2013 13:40-14:40 Mo
Page 84 and 85:
Monday, June 3, 2013 13:40-14:40 Mo
Page 86 and 87:
Tuesday, June 4, 2013 12:40-13:40 M
Page 88 and 89:
Tuesday, June 4, 2013 12:40-13:40 M
Page 90 and 91:
Tuesday, June 4, 2013 12:40-13:40 M
Page 92 and 93:
Tuesday, June 4, 2013 12:40-13:40 M
Page 94 and 95:
Tuesday, June 4, 2013 12:40-13:40 M
Page 96 and 97:
Tuesday, June 4, 2013 13:40-14:40 M
Page 98 and 99:
Tuesday, June 4, 2013 13:40-14:40 M
Page 100 and 101:
Tuesday, June 4, 2013 13:40-14:40 M
Page 102 and 103:
Tuesday, June 4, 2013 13:40-14:40 M
Page 104 and 105:
Monday, June 3 - Wednesday, June 5,
Page 106 and 107:
POSTERS TRACK 1 VASCULAR BIOLOGY OF
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
POSTERS TRACK 2 LIPID AND LIPOPROTE
Page 120 and 121:
POSTERS TRACK 2: LIPID AND LIPOPROT
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
POSTERS TRACK 3: RISK FACTORS, EPID
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
L Arteriosclerosis, Thrombosis, and
Page 180 and 181:
Al-Jenabi, A. .....................
Page 182 and 183:
Barter, P. ........................
Page 184 and 185:
Bouillet, B. ......................
Page 186 and 187:
Changarotti, J. ...................
Page 188 and 189:
Cuniberti, L. .....................
Page 190 and 191:
Dubois, N. ........................
Page 192 and 193:
Fjornes, T. .......................
Page 194 and 195:
Gogou, M. .........................
Page 196 and 197:
Heeren, J. ........................
Page 198 and 199:
Ito, Y. ...........................
Page 200 and 201:
Kaudewitz, D. .....................
Page 202 and 203:
Krajcoviechova, A. ................
Page 204 and 205:
Lewis, G. .........................
Page 206 and 207:
Mallol, R. ........................
Page 208 and 209:
Mikołajczyk, T. ..................
Page 210 and 211:
Nash, G. ..........................
Page 212 and 213:
Østerud, B. ......................
Page 214 and 215:
Picard, P. ........................
Page 216 and 217:
Ribalta, J. .......................
Page 218 and 219:
Saponaro, C. ......................
Page 220 and 221:
Skrbic, R. ........................
Page 222 and 223:
Tang, Z.H. ........................
Page 224 and 225:
V Vacula, I. ......................
Page 226 and 227:
Wang, K.-Y. .......................
Page 228:
Zeiher, A. ........................
show all

FINAL PROGRAMME

Create successful ePaper yourself

Delete template?

Save as template?